Idiotypic DNA vaccination for the treatment of multiple myeloma: Safety and immunogenicity in a phase I clinical study

Cancer Immunology, Immunotherapy

Volumn 64, Issue 8, 2015, Pages 1021-1032

  McCann, Katy J ^a   Godeseth, Rosemary ^a,b   Chudley, Lindsey ^a   Mander, Ann ^a   Di Genova, Gianfranco ^a   Lloyd Evans, Paul ^c   Kerr, Jonathan P ^d   Malykh, Vladimir B ^b   Jenner, Matthew W ^b   Orchard, Kim H ^b   Stevenson, Freda K ^a   Ottensmeier, Christian H ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cancer vaccine; DNA vaccine; Idiotype; Immunotherapy; Multiple myeloma

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN IDIOTYPE; PARAPROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TETANUS TOXIN; CANCER VACCINE; HYBRID PROTEIN; PEPTIDE FRAGMENT; TETANUS TOXIN FRAGMENT C;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ANTIBODY DETECTION; ARTHRALGIA; ARTHRITIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACKACHE; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; CONFUSION; COUGHING; DEPRESSION; DIARRHEA; DNA IMMUNIZATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; EYE INFECTION; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GINGIVITIS; HERPES ZOSTER; HUMAN; HUMAN CELL; HYPERTENSION; IMMUNE RESPONSE; IMMUNOGENICITY; INFESTATION; INJECTION SITE ERYTHEMA; INJECTION SITE RASH; INJECTION SITE REACTION; LETHARGY; LUNG INFECTION; MACULOPAPULAR RASH; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NEURALGIA; OVERALL SURVIVAL; PERIODONTAL DISEASE; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PRURITUS; SHOULDER PAIN; SIDE EFFECT; SORE THROAT; T LYMPHOCYTE; TACHYCARDIA; THORAX PAIN; THROMBOEMBOLISM; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; CANCER STAGING; CLINICAL TRIAL; FOLLOW UP; GENETICS; HUMORAL IMMUNITY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MORTALITY; SURVIVAL;

ADULT; AGED; CANCER VACCINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN IDIOTYPES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TETANUS TOXIN; VACCINES, DNA;

EID: 84937967531     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1703-7     Document Type: Article

References (45)

1. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ, Medical Research Council Adult Leukaemia Working Party (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875–1883
2. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, Belanger C, Janvier M, Chevret S, Brouet JC, Ravaud P, Group M-A (2005) High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55–65Âyears: Long-term results of a randomized control trial from the group myelome-autogreffe. J Clin Oncol 23:9227–9233
3. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516–2520
4. Bird JM, Owen RG, D’Sa S, Snowden JA, Pratt G, Ashcroft J, Yong K, Cook G, Feyler S, Davies F, Morgan G, Cavenagh J, Low E, Behrens J, Haemato-oncology Task Force of British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum (2011) Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 154:32–75
5. Eisen HN, Sakato N, Hall SJ (1975) Myeloma proteins as tumor-specific antigens. Transplant Proc 7:209–214
6. George AJ, Stevenson FK (1989) Prospects for the treatment of B cell tumors using idiotypic vaccination. Int Rev Immunol 4:271–310
7. King CA, Spellerberg MB, Zhu D, Rice J, Sahota SS, Thompsett AR, Hamblin TJ, Radl J, Stevenson FK (1998) DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 4:1281–1286
8. Cohen S, Haimovich J, Hollander N (2005) B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice. J Immunother 28:461–466
9. Inoges S, Rodriguez-Calvillo M, Zabalegui N, Lopez-Diaz de Cerio A, Villanueva H, Soria E, Suarez L, Rodriguez-Caballero A, Pastor F, Garcia-Munoz R, Panizo C, Perez-Calvo J, Melero I, Rocha E, Orfao A, Bendandi M, Espanol Grupo, de Linfomas Trasplante, de Medula Autologo, Grupo Español de Linfomas/Trasplante Autologo de Medula Oseo study group, Programa para el Estudio y Tratamiento de Hemopatias Malignas study group (2006) Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst 98:1292–1301
10. Bogen B, Ruffini PA, Corthay A, Fredriksen AB, Froyland M, Lundin K, Rosjo E, Thompson K, Massaia M (2006) Idiotype-specific immunotherapy in multiple myeloma: Suggestions for future directions of research. Haematologica 91:941–948
11. Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R (1997) Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma–long-term results of a clinical trial. Blood 89:3129–3135
12. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, McGaughey DS, Jaffe ES, Chong EA, Reynolds CW, Berry DA, Santos CF, Popa MA, McCord AM, Kwak LW (2011) Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 29:2787–2794
13. Ocqueteau M, San Miguel JF, Gonzalez M, Almeida J, Orfao A (1996) Do myelomatous plasma cells really express surface immunoglobulins? Haematologica 81:460–463
14. Wen YJ, Barlogie B, Yi Q (2001) Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: Evidence for their capacity to lyse autologous primary tumor cells. Blood 97:1750–1755
15. Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, Omholt H, Munthe LA, Dembic Z, Corthay A, Bogen B (2014) How do CD4(+) T cells detect and eliminate tumor cells that either lack or express MHC class II molecules? Front Immunol 5:174
16. Rhee F (2007) Idiotype vaccination strategies in myeloma: How to overcome a dysfunctional immune system. Clin Cancer Res 13:1353–1355
17. Coscia M, Mariani S, Battaglio S, Di Bello C, Fiore F, Foglietta M, Pileri A, Boccadoro M, Massaia M (2004) Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia 18:139–145
18. Hansson L, Abdalla AO, Moshfegh A, Choudhury A, Rabbani H, Nilsson B, Osterborg A, Mellstedt H (2007) Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clin Cancer Res 13:1503–1510
19. Stevenson FK, Ottensmeier CH, Johnson P, Zhu D, Buchan SL, McCann KJ, Roddick JS, King AT, McNicholl F, Savelyeva N, Rice J (2004) DNA vaccines to attack cancer. Proc Natl Acad Sci USA 101(Suppl. 2):14646–14652
20. Hawkins RE, Zhu D, Ovecka M, Winter G, Hamblin TJ, Long A, Stevenson FK (1994) Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood 83:3279–3288
21. Spellerberg MB, Zhu D, Thompsett A, King CA, Hamblin TJ, Stevenson FK (1997) DNA vaccines against lymphoma: Promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. J Immunol 159:1885–1892
22. Bogen B (1996) Peripheral T cell tolerance as a tumor escape mechanism: Deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol 26:2671–2679
23. Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ, Old LJ, Romero P, Hoos A, Davis MM (2009) “MIATA”—minimal information about T cell assays. Immunity 31:527–528
24. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (1999) The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. Ann Oncol 10:1419–1432
25. Guillaume T, Rubinstein DB, Symann M (1998) Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 92:1471–1490
26. Sahota SS, Townsend M, Stevenson FK (2005) Identification and assembly of V genes as idiotype-specific DNA fusion vaccines in multiple myeloma. Methods Mol Med 113:105–119
27. McCann KJ, Ottensmeier CH, Callard A, Radcliffe CM, Harvey DJ, Dwek RA, Rudd PM, Sutton BJ, Hobby P, Stevenson FK (2008) Remarkable selective glycosylation of the immunoglobulin variable region in follicular lymphoma. Mol Immunol 45:1567–1572
28. Mander A, Chowdhury F, Low L, Ottensmeier CH (2009) Fit for purpose? A case study: Validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines. Cancer Immunol Immunother 58:789–800
29. Russell ND, Hudgens MG, Ha R, Havenar-Daughton C, McElrath MJ (2003) Moving to human immunodeficiency virus type 1 vaccine efficacy trials: Defining T cell responses as potential correlates of immunity. J Infect Dis 187:226–242
30. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412–3420
31. Arrowood JR, Hayney MS (2002) Immunization recommendations for adults with cancer. Ann Pharmacother 36:1219–1229
32. Stevenson FK, Di Genova G, Ottensmeier CH, Savelyeva N (2007) Cancer Vaccines. In: Prendergast GC, Jaffee EM (eds) Cancer immunotherapy: immune suppression and tumor growth, 1st edn. Elsevier, London, pp 183–204
33. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R (2002) Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients. Blood 99:1517–1526
34. Abdalla AO, Hansson L, Eriksson I, Nasman-Glaser B, Mellstedt H, Osterborg A (2007) Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients. Eur J Haematol 79:371–381
35. Robertson JD, Nagesh K, Jowitt SN, Dougal M, Anderson H, Mutton K, Zambon M, Scarffe JH (2000) Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer 82:1261–1265
36. Moshitzky S, Kukulansky T, Haimovich J, Hollander N (2008) Growth inhibition of myeloma cells by anti-idiotype antibodies in the absence of membrane-bound immunoglobulin. Immunol Cell Biol 86:261–267
37. Abdalla AO, Kokhaei P, Hansson L, Mellstedt H, Osterborg A (2008) Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC). Ann Oncol 19:1172–1179
38. Bogen B, Malissen B, Haas W (1986) Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur J Immunol 16:1373–1378
39. Osterborg A, Yi Q, Bergenbrant S, Holm G, Lefvert AK, Mellstedt H (1995) Idiotype-specific T cells in multiple myeloma stage I: An evaluation by four different functional tests. Br J Haematol 89:110–116
40. Abdalla AO, Hansson L, Eriksson I, Nasman-Glaser B, Rossmann ED, Rabbani H, Mellstedt H, Osterborg A (2007) Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma—evaluation of T-cell responses by different read-out systems. Haematologica 92:110–114
41. Titzer S, Christensen O, Manzke O, Tesch H, Wolf J, Emmerich B, Carsten C, Diehl V, Bohlen H (2000) Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: Immunological and clinical aspects. Br J Haematol 108:805–816
42. Munshi NC, Anderson KC (2013) New strategies in the treatment of multiple myeloma. Clin Cancer Res 19:3337–3344
43. Fioretti D, Iurescia S, Fazio VM, Rinaldi M (2010) DNA vaccines: Developing new strategies against cancer. J Biomed Biotechnol 2010:174378
44. Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, Genuardi M, Cafro A, Marcatti M, Catalano L, Offidani M, Carella AM, Zamagni E, Patriarca F, Musto P, Evangelista A, Ciccone G, Omede P, Crippa C, Corradini P, Nagler A, Boccadoro M, Cavo M (2014) Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 371:895–905
45. Noonan K, Rudraraju L, Ferguson A, Emerling A, Pasetti MF, Huff CA, Borrello I (2012) Lenalidomide-induced immunomodulation in multiple myeloma: Impact on vaccines and antitumor responses. Clin Cancer Res 18:1426–1434